FcRn News and Research

RSS

Placental biology breakthrough could make biologic medicines safer during pregnancy

Biologic medicines have transformed the treatment of cancer, autoimmune diseases, migraine, inflammatory disorders and many other diseases.

14 Aug 2026

Mount Sinai study links long COVID symptoms to autoimmunity

A Mount Sinai-led research team has demonstrated that autoimmunity, where the body's immune system attacks its own tissues, is responsible for the often-debilitating and confounding symptoms of long COVID in a subset of people.

28 May 2026

Rozanolixizumab prevents congenital heart block in high-risk pregnancy

Congenital heart block, sometimes referred to as cardiac neonatal lupus, is a rare but potentially life-threatening condition that affects babies born to mothers with specific autoantibodies - called anti-SSA/Ro antibodies - which can attack the fetal heart via its electrical conduction system, leading to a slower heart rate.

22 Oct 2025

How shifting antibodies fuel aging and the new therapies aiming to slow it

This review uncovers how aging reshapes immunoglobulins, particularly IgG, IgM, and IgA, driving inflammation, cellular senescence, and tissue degeneration. By dissecting B-cell dysfunction, glycosylation changes, and Fc receptor pathways, it reveals immunoglobulins as both biomarkers and potential therapeutic targets in aging.

14 Oct 2025

Researchers design factor IX variants for short- and long-term Hemophilia B management

After blood vessel damage, effective blood clotting is essential to halt bleeding. However, this process is inefficient in some individuals due to hereditary factors. Hemophilia B, for example, results from a deficiency in coagulation factor IX (FIX), which can lead to prolonged bleeding after injuries or surgery.

30 Sep 2025

New albumin-based vaccine shows promise for mucosal immunity

Vaccines save millions of lives every year, but there is still an urgent need for more efficient vaccines. Strategies to combat serious outbreaks of viral infections are particularly important.

2 May 2025

Critical protein linked to spillover potential of animal viruses

Scientists investigating animal viruses with potential to infect humans have identified a critical protein that could enable spillover of a family of organisms called arteriviruses.

1 Nov 2024

Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis

The BLA submission for nipocalimab marks a significant advancement in treating generalized myasthenia gravis, showing improved MG-ADL scores in clinical trials.

From Johnson & Johnson 24 Sep 2024

New insights into stiff-person syndrome, advancing diagnosis and treatment

Research explores the complexities of diagnosing and treating stiff-person syndrome, emphasizing the uncertain role of GAD antibodies and the promise of novel therapies.

5 Sep 2024

Revolutionary blood test monitors gene expression dynamics in the brain

The brain is the most protected organ in the body, sheathed in a complex and nearly impenetrable barrier of specialized blood vessels.

11 Jan 2024

New nasal vaccine for COVID-19 shows promise in animal studies

A team of University of Maryland researchers developed a nasal spray vaccine that delivers the SARS-CoV-2 spike protein into cells of the airway in mice and hamsters, triggering an immune response that significantly reduced infection and spread of COVID-19.

6 Nov 2023

Study suggests SARS-CoV-2 vaccination in pregnancy induces diverging maternal and infant cord antibody functions

Researchers explored the differences in infant and maternal cord antibody functions between SARS-CoV-2 infection and vaccination during pregnancy.

4 May 2023

New study suggests broad neutralizing antibody could provide three years of COVID protection

In a recent article published in the journal Science Translational Medicine, researchers showed that a novel, lab-engineered monoclonal antibody (mAb), adintrevimab conferred up to 50% protection against symptomatic coronavirus disease 2019 (COVID-19). Furthermore, it demonstrated this exceptional efficacy in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–naïve individuals even at titers as low as 1:30.

27 Mar 2023

Disruption of the FcRn–IgG interaction may make AAV-based gene therapies effective

The use of a monoclonal antibody that reduced circulating IgG levels, led to a decrease in preexisting neutralizing antibodies (NAbs) to adeno-associated virus (AAV).

22 Mar 2023

Researcher contextualizes a study on IgG4 anti-Spike levels after repeated SARS-CoV-2 mRNA vaccination

A researchers emphasized the need to reconsider mRNA COVID-19 vaccination strategies in the future,

9 Feb 2023

Vaccination against pertussis in pregnancy and outstanding scientific questions

A recent paper published in Vaccines summarized the data presented and the discussions in the meeting regarding pertussis vaccination in pregnancy (ViP).

2 Dec 2022

Combination of multi-specificity and antibody avidity enhances protection against SARS-CoV-2

In a recent study posted to the bioRxiv* preprint server, an international team of researchers leveraged the human light chain apoferritin protomer-derived MULTI-specific, multi-Affinity antibody (Multabody, MB) platform for the generation of broad and potent SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2)-neutralizing antibodies (Abs).

27 Oct 2022